Zevra Therapeutics
Adrian Quartel has extensive work experience in the medical field. Adrian is currently serving as the Chief Medical Officer at Zevra Therapeutics since 2024. Prior to this role, they held the same position at Acer Therapeutics Inc. from 2022 to 2024, and at Adamas Pharmaceuticals, Inc. from 2020 to 2022. Adrian also has experience working at BioMarin Pharmaceutical Inc., where they held various leadership roles in medical affairs from 2007 to 2020. Before that, they worked at Chiltern int as the Medical Director UK, Astellas Pharma as the European Medical Affairs Manager, ICON Clinical Research as a Senior Clinical Research Physician, and California Clinical Trials as a Clinical Research Coordinator. Adrian began their career as a SHO Thoracic Surgery at Erasmus MC and later worked as a Research Fellow at Cedars-Sinai Medical Center.
Adrian Quartel completed their Doctor of Medicine (M.D.) degree in medicine from Erasmus University Rotterdam between 1988 and 1996. Adrian then pursued further education at Cardiff University / Prifysgol Caerdydd from 2004 to 2006. Adrian then attended the Royal College of Physicians from 2006 to 2012, studying Pharmaceutical Medicine. Finally, they became a Fellow of the Faculty of Pharmaceutical Medicine in 2017.
This person is not in any offices
Zevra Therapeutics
1 followers
We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.